Medical Hemostatic Agents Sales

Medical Hemostatic Agents Sales Market Outlook

The global Medical Hemostatic Agents market is projected to reach approximately USD 7.1 billion by 2035, growing at a compound annual growth rate (CAGR) of around 5.8% during the forecast period from 2025 to 2035. This growth can be attributed to an increase in surgical procedures, a rising geriatric population, and growing awareness of advanced hemostatic products that improve patient outcomes. The need for effective hemostatic solutions in emergency care settings and the rapid development of innovative products are also driving market expansion. As a result, hospitals and surgical facilities are increasingly adopting these agents to minimize bleeding during surgical interventions and enhance recovery times for patients, further fostering market growth. The global focus on improving surgical outcomes is expected to contribute significantly to the rising demand for medical hemostatic agents.

Growth Factor of the Market

Several key factors are fueling the growth of the Medical Hemostatic Agents market. Firstly, the rise in the number of surgical procedures performed globally, especially in the fields of cardiovascular, orthopedic, and general surgeries, necessitates the use of effective hemostatic agents to control bleeding. Secondly, with an aging population that is more prone to various health issues requiring surgical intervention, the demand for hemostatic solutions is expected to rise. Additionally, the growing awareness among healthcare professionals about the advantages of using advanced hemostatic agents is influencing their adoption in surgical practices. The innovation and development of new products designed to provide enhanced efficacy and safety profiles are also significant contributors to market growth. Lastly, the increasing incidence of trauma and emergency surgeries is pushing healthcare providers to rely on effective hemostatic agents, thereby driving the market forward.

Key Highlights of the Market

• The global Medical Hemostatic Agents market is projected to reach USD 7.1 billion by 2035.
• The market is expected to grow at a CAGR of 5.8% from 2025 to 2035.
• Increasing surgical procedures and a growing geriatric population are key growth drivers.
• Advancements in hemostatic product technology are enabling improved patient outcomes.
• The rising incidence of trauma cases is increasing the demand for effective hemostatic solutions.

By Product Type

Thrombin-Based Hemostats:

Thrombin-based hemostats are among the most widely used agents for controlling bleeding during surgical procedures. These agents utilize the natural clotting process and facilitate rapid hemostasis by promoting fibrin clot formation. The growing preference for minimally invasive surgical techniques is boosting the demand for thrombin-based hemostats, as they are known for their effectiveness in managing bleeding with reduced tissue trauma. Their versatility in various surgical disciplines, including cardiovascular and orthopedic surgeries, further enhances their market appeal. Additionally, the introduction of advanced formulations that improve performance and reduce the risk of adverse reactions is contributing to the growth of this segment.

Oxidized Regenerated Cellulose-Based Hemostats:

Oxidized regenerated cellulose-based hemostats are gaining traction due to their excellent hemostatic properties and biocompatibility. These agents are made from oxidized cellulose, which promotes clot formation and provides a temporary barrier to bleeding. They are particularly effective in surgeries involving highly vascular tissues, such as in cardiovascular and gynecological procedures. The ability to be absorbed by the body without the need for surgical removal makes these hemostats favorable among surgeons. The increasing number of surgical procedures and an emphasis on minimizing postoperative complications are expected to drive the demand for oxidized regenerated cellulose-based hemostats in the coming years.

Gelatin-Based Hemostats:

Gelatin-based hemostats are derived from the hydrolysis of collagen and are known for their excellent hemostatic properties. They are typically used in surgeries to provide rapid hemostasis, particularly in soft tissue procedures. The ease of application and biocompatibility of gelatin-based hemostats are among the factors contributing to their rising popularity. Additionally, advancements in formulation to enhance their performance and reduce potential side effects are attracting more healthcare providers towards using these agents. The increasing prevalence of surgical procedures and the need for effective bleeding control strategies are major drivers for this product type.

Collagen-Based Hemostats:

Collagen-based hemostats are natural hemostatic agents that promote hemostasis through the activation of the coagulation cascade. These agents enhance the body’s natural healing processes and are particularly effective in surgeries where rapid hemostatic action is required. Collagen hemostats are often utilized in orthopedic, dental, and plastic surgeries. Their ability to promote cell adhesion and migration also makes them beneficial in wound healing processes. The rising preference for natural and biocompatible products among surgeons and the increasing number of surgical procedures are anticipated to propel the growth of collagen-based hemostats in the market.

Synthetic Hemostats:

Synthetic hemostats are innovative agents that have gained popularity in recent years due to their tailored properties and enhanced performance. These hemostats are designed to provide rapid hemostatic action and are often utilized in complex surgical procedures. Their ability to be produced in various forms, such as gels, powders, and sprays, offers versatility in application. The rising demand for advanced surgical products and the continuous innovations in synthetic formulations are key drivers of the synthetic hemostats segment. Additionally, the increasing adoption of minimally invasive surgical techniques is expected to further boost the use of synthetic hemostatic agents in the healthcare sector.

By Application

Trauma:

The trauma application segment is a significant contributor to the Medical Hemostatic Agents market, driven by the increasing incidence of traumatic injuries and emergency cases. Hemostatic agents are critical in emergency medical situations, as they effectively control bleeding and stabilize patients before they reach surgical facilities. The growing prevalence of road accidents, falls, and violent incidents has led to a heightened demand for trauma care, which, in turn, boosts the use of hemostatic agents. Innovations in product development aimed at improving the speed and efficiency of hemostatic action further support the growth of this segment.

Cardiovascular Surgery:

Cardiovascular surgery is another vital application area for medical hemostatic agents, as these procedures often involve significant blood loss. Hemostatic agents are essential for managing bleeding during surgery, helping to ensure patient safety and successful outcomes. The increasing prevalence of cardiovascular diseases worldwide and the growing number of surgical interventions, including bypass surgeries and valve replacements, are propelling the demand for effective hemostatic solutions. As advancements in surgical techniques continue to evolve, the reliance on hemostatic agents will likely increase, enhancing their importance within this application segment.

General Surgery:

In the realm of general surgery, hemostatic agents play a crucial role in managing bleeding and enhancing surgical efficiency. These agents are employed across various procedures, ranging from appendectomies to gallbladder removals. The shift towards minimally invasive surgical techniques is further increasing the adoption of hemostatic products, as they help minimize blood loss and reduce recovery times. Additionally, as surgical techniques evolve, the demand for advanced hemostatic agents that can effectively meet the needs of surgeons is also on the rise. The expansion of this segment is supported by the continuous growth in the number of general surgeries performed globally.

Plastic Surgery:

Plastic surgery, known for its complexity and the potential for significant blood loss, is a key application area for medical hemostatic agents. These agents are utilized to control bleeding during aesthetic and reconstructive procedures, ensuring optimal surgical outcomes. The rise in cosmetic procedures and reconstructive surgeries is driving the demand for effective hemostatic solutions in this sector. Moreover, as patients become more aware of the options available for enhancing their appearance, the number of procedures performed is expected to continue to grow. This trend is likely to further boost the need for hemostatic agents designed specifically for plastic surgery applications.

Orthopedic Surgery:

Orthopedic surgery significantly contributes to the demand for medical hemostatic agents, as these procedures often involve major blood vessels and extensive tissue manipulation. Hemostatic agents are crucial for managing bleeding during operations such as joint replacements, spinal surgeries, and fracture repairs. The growing incidence of orthopedic conditions, including arthritis and sports injuries, is driving the volume of orthopedic surgeries performed globally. Additionally, advancements in surgical techniques and technologies are encouraging the adoption of hemostatic agents that facilitate faster recovery times and improved patient outcomes. This trend highlights the importance of hemostatic agents in orthopedic applications.

By Distribution Channel

Hospitals:

Hospitals represent one of the largest distribution channels for medical hemostatic agents, with a significant portion of the market share. These institutions are primary settings for surgical procedures, necessitating a consistent supply of hemostatic products to manage bleeding effectively. The increasing number of surgical interventions performed in hospitals, combined with the growing emphasis on patient safety and care quality, drives the demand for hemostatic agents in this channel. Additionally, hospitals often have the infrastructure and resources to evaluate and adopt advanced hemostatic solutions, paving the way for greater market penetration.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming increasingly popular for outpatient surgeries and are an essential distribution channel for hemostatic agents. These centers provide a cost-effective alternative to traditional hospital settings while meeting the growing demand for same-day surgical procedures. As the trend toward outpatient surgeries rises, the need for effective hemostatic solutions in ASCs is also increasing. The focus on patient safety and efficient surgical practices within these centers further enhances the demand for reliable hemostatic agents, contributing to market growth in this distribution channel.

Specialty Clinics:

Specialty clinics play a vital role in the distribution of medical hemostatic agents, particularly for specific surgical fields such as dermatology, orthopedics, and gastrointestinal procedures. These clinics often perform specialized surgeries that require tailored hemostatic solutions to ensure successful outcomes. The rise in specialty procedures and the growing focus on personalized care is propelling the demand for hemostatic agents in this sector. Furthermore, as these clinics adopt advanced surgical techniques, the need for innovative and effective hemostatic products is expected to continue to grow, emphasizing the importance of this distribution channel.

Online Stores:

The online distribution channel for medical hemostatic agents is rapidly expanding as healthcare providers increasingly turn to e-commerce platforms for their supplies. The convenience of online shopping, along with the ability to access a broader range of products, is driving the growth of this channel. Online stores provide significant advantages, including competitive pricing and expedited delivery options, which appeal to healthcare professionals seeking efficient procurement methods. As more healthcare providers embrace digital solutions, the online distribution channel for medical hemostatic agents is expected to witness substantial growth in the coming years.

Retail Pharmacies:

Retail pharmacies are a critical distribution channel for medical hemostatic agents, particularly for over-the-counter products intended for minor wounds and injuries. As consumers become more health-conscious and proactive about managing their health, the demand for accessible hemostatic solutions in retail settings is increasing. Retail pharmacies offer convenience for patients seeking quick access to hemostatic products, contributing to the growth of this distribution channel. The continuous expansion of pharmacy services, including consultations and health screenings, further strengthens the role of retail pharmacies as a key distribution channel for hemostatic agents.

By Ingredient Type

Plant-Based:

Plant-based hemostatic agents are gaining popularity due to the increasing demand for natural and biocompatible products. These agents harness the hemostatic properties of plant-derived substances, making them suitable for use in various surgical applications. Their biocompatibility and reduced risk of allergic reactions make them especially appealing to both surgeons and patients. As the trend towards natural products continues to rise, the market for plant-based hemostatic agents is expected to expand, driven by the growing preference of healthcare professionals for safer and more effective hemostatic solutions.

Animal-Based:

Animal-based hemostatic agents are traditionally used in surgical procedures and are known for their effectiveness in promoting clot formation. These agents are typically derived from animal tissues, such as collagen or thrombin, and have a long history of successful application in various surgeries. While they are effective, there are concerns regarding the potential for allergic reactions and disease transmission. Nonetheless, as surgical practices evolve and the need for reliable hemostatic solutions grows, the demand for animal-based hemostatic agents remains strong. Continuous research and development efforts are focusing on enhancing the safety and efficacy of these agents in clinical settings.

Synthetic:

Synthetic hemostatic agents are an innovative solution designed to provide rapid and effective hemostasis during surgical procedures. These agents are engineered to enhance performance and minimize adverse effects, making them an attractive choice for surgeons. The versatility of synthetic hemostatic agents allows for various formulations, including gels, powders, and films, catering to different surgical needs. As the healthcare industry increasingly adopts advanced technologies and seeks to improve patient outcomes, the synthetic hemostatic agents segment is expected to witness significant growth. The continuous innovation in this area is pivotal in elevating the standard of surgical care.

By Region

The North American region holds a substantial share of the Medical Hemostatic Agents market, driven by advanced healthcare infrastructure, a high volume of surgical procedures, and increasing awareness of innovative hemostatic products. The market in North America is projected to grow at a CAGR of 6.2%, significantly reflecting the region's commitment to improving patient care and surgical outcomes. The presence of prominent market players and ongoing investments into research and development further bolster growth in this region. Additionally, the escalating incidence of chronic diseases requiring surgical intervention is anticipated to amplify the demand for hemostatic agents, creating lucrative opportunities for market participants.

In Europe, the Medical Hemostatic Agents market is also experiencing robust growth, primarily propelled by the increasing number of surgical procedures and the rising prevalence of cardiovascular and orthopedic conditions. The European market is characterized by the presence of well-established healthcare systems and a growing emphasis on patient safety and recovery. The market value in Europe is estimated to reach approximately USD 2.0 billion by 2035. Regions like Asia Pacific are witnessing rapid growth due to the rise in healthcare spending, improving medical facilities, and increasing surgical intervention rates. Collectively, these regions are anticipated to contribute significantly to the overall growth of the Medical Hemostatic Agents market.

Opportunities

The Medical Hemostatic Agents market is poised for substantial growth driven by numerous opportunities on the horizon. One of the most significant opportunities lies in the realm of product innovation and development. The continuous evolution of surgical techniques necessitates the development of advanced hemostatic agents that can adapt to the changing needs of healthcare providers. This opens the door for companies to invest in research and development, focusing on creating novel formulations with superior efficacy and safety profiles. Additionally, the increasing adoption of minimally invasive surgical procedures presents an opportunity for hemostatic agents that cater specifically to these techniques, as they require rapid and effective bleeding control while minimizing tissue trauma.

Moreover, the expanding awareness of hemostatic solutions among healthcare professionals is another opportunity that can be capitalized on. As surgeons and medical practitioners recognize the importance of effective hemostatic agents in improving patient outcomes, the demand for these products is expected to rise. Furthermore, emerging markets, particularly in the Asia Pacific and Latin America regions, present untapped potential for market growth. The increasing healthcare expenditures and improving medical infrastructures in these regions will likely lead to a higher volume of surgical procedures, consequently driving the demand for medical hemostatic agents. Companies that strategically position themselves in these emerging markets stand to gain a competitive advantage as the demand for effective hemostatic solutions continues to grow.

Threats

While the Medical Hemostatic Agents market presents numerous growth opportunities, it is not without its challenges and threats. One major threat is the increasing competition among key market players, which can lead to price wars and reduced profit margins. As more companies enter the market with similar products, differentiating offerings becomes crucial. This competition may also drive a focus on cost-cutting measures rather than product innovation, potentially hindering advancements in the sector. Furthermore, the regulatory landscape surrounding medical products and hemostatic agents is becoming increasingly stringent, which may pose challenges for companies looking to introduce new products or expand into new markets. Compliance with these regulations requires substantial investments, which may not always yield proportional returns.

In addition to competitive pressures and regulatory challenges, the market also faces threats related to the availability of alternative treatments and therapies. The advent of novel therapeutic approaches, including advanced surgical techniques that minimize bleeding risk or the use of other medical devices, can impact the demand for traditional hemostatic agents. This shift may compel companies to adapt their strategies to remain relevant in a rapidly evolving healthcare landscape. Moreover, concerns about the safety and efficacy of certain hemostatic agents may lead to a decline in their use if perceived risks outweigh the benefits in the eyes of healthcare professionals and patients. Addressing these threats will require proactive strategies and a focus on delivering high-quality, safe, and effective hemostatic solutions to the market.

Competitor Outlook

• Ethicon (Johnson & Johnson)
• Medtronic
• Hemostasis, Inc.
• Cohera Medical
• Covidien (Medtronic)
• CSL Behring
• Alphatec Spine
• Integra LifeSciences
• Gelita Medical
• Baxter International
• Biocoat, Inc.
• Angiotech
• Advanced Medical Solutions Group plc
• Hemostatic Solutions, Inc.
• Marine Polymer Technologies, Inc.

The competitive landscape of the Medical Hemostatic Agents market is characterized by a mix of established players and emerging companies striving to innovate and capture market share. Major companies such as Ethicon and Medtronic dominate the market, leveraging their extensive product portfolios and strong distribution networks. These companies invest heavily in research and development to enhance their product offerings and maintain a competitive edge in the market. Moreover, strategic mergers and acquisitions among key players are reshaping the competitive dynamics, as they seek to consolidate resources and expand their product reach.

In addition to large manufacturers, several smaller companies are gaining traction by introducing niche products that cater to specific surgical applications. These companies focus on developing specialized hemostatic agents that address unique challenges faced by surgeons. For instance, companies like Cohera Medical and Advanced Medical Solutions Group plc are known for their innovative approaches to hemostatic solutions, emphasizing biocompatibility and ease of use. As the market evolves, these emerging players are expected to continue challenging the established order, fostering an environment of innovation and competition.

Furthermore, the growing emphasis on patient-centered care and outcomes is pushing companies to develop products that not only control bleeding effectively but also minimize complications and enhance recovery. Companies such as Baxter International and Integra LifeSciences are investing in technologies that facilitate rapid absorption and enhance the healing process. The competitive dynamics of the Medical Hemostatic Agents market will continue to evolve, shaped by the interplay of innovation, regulatory considerations, and evolving healthcare needs.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Angiotech
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 CSL Behring
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Biocoat, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Alphatec Spine
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Cohera Medical
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Gelita Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Hemostasis, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Baxter International
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Covidien (Medtronic)
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Integra LifeSciences
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hemostatic Solutions, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Ethicon (Johnson & Johnson)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Marine Polymer Technologies, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Advanced Medical Solutions Group plc
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Medical Hemostatic Agents Sales Market, By Application
    • 6.1.1 Trauma
    • 6.1.2 Cardiovascular Surgery
    • 6.1.3 General Surgery
    • 6.1.4 Plastic Surgery
    • 6.1.5 Orthopedic Surgery
  • 6.2 Medical Hemostatic Agents Sales Market, By Product Type
    • 6.2.1 Thrombin-Based Hemostats
    • 6.2.2 Oxidized Regenerated Cellulose-Based Hemostats
    • 6.2.3 Gelatin-Based Hemostats
    • 6.2.4 Collagen-Based Hemostats
    • 6.2.5 Synthetic Hemostats
  • 6.3 Medical Hemostatic Agents Sales Market, By Ingredient Type
    • 6.3.1 Plant-Based
    • 6.3.2 Animal-Based
    • 6.3.3 Synthetic
  • 6.4 Medical Hemostatic Agents Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Stores
    • 6.4.5 Retail Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Medical Hemostatic Agents Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Medical Hemostatic Agents Sales market is categorized based on

By Product Type

• Thrombin-Based Hemostats
• Oxidized Regenerated Cellulose-Based Hemostats
• Gelatin-Based Hemostats
• Collagen-Based Hemostats
• Synthetic Hemostats

By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Stores
• Retail Pharmacies

By Ingredient Type

• Plant-Based
• Animal-Based
• Synthetic

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Ethicon (Johnson & Johnson)
• Medtronic
• Hemostasis, Inc.
• Cohera Medical
• Covidien (Medtronic)
• CSL Behring
• Alphatec Spine
• Integra LifeSciences
• Gelita Medical
• Baxter International
• Biocoat, Inc.
• Angiotech
• Advanced Medical Solutions Group plc
• Hemostatic Solutions, Inc.
• Marine Polymer Technologies, Inc.